Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $14354.0.

  • BioNexus Gene Lab's Amortizatization of Intangibles fell 305.94% to $14354.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $55142.0, marking a year-over-year increase of 2238.28%. This contributed to the annual value of $48983.0 for FY2024, which is 9460.87% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Amortizatization of Intangibles stood at $14354.0 for Q3 2025, which was down 305.94% from $13933.0 recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Amortizatization of Intangibles peaked at $14807.0 during Q3 2024, and registered a low of $1238.0 during Q4 2022.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $4434.0 (2021), whereas its average is $7723.4.
  • Per our database at Business Quant, BioNexus Gene Lab's Amortizatization of Intangibles crashed by 6673.83% in 2022 and then soared by 67140.55% in 2023.
  • BioNexus Gene Lab's Amortizatization of Intangibles (Quarter) stood at $3722.0 in 2021, then crashed by 66.74% to $1238.0 in 2022, then surged by 671.41% to $9550.0 in 2023, then surged by 41.11% to $13476.0 in 2024, then grew by 6.52% to $14354.0 in 2025.
  • Its Amortizatization of Intangibles stands at $14354.0 for Q3 2025, versus $13933.0 for Q2 2025 and $13379.0 for Q1 2025.